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Clinical Ethics
THERE IS GROWING DEBATE about the ethics of relation-
ships between the pharmaceutical industry and the medical
profession.1,2 Concerns include bias in research funded by
the pharmaceutical i dustry3 and conflicts of interest with
regard to prescribing by medical practitioners who accept
industry gifts and hospitality.4,5 The ethical bott  line is
that this relationship can and does lead to harm to patients:
at an individual level through inappropriate prescribing,6
and at a social level through the rising opportunity costs
associated with the unwarranted use of more expensive
pharmaceuticals.7
To date, there has been little debate about the ethics of
pharmaceutical industry relationships with medical stu-
dents. After all, students are not in a position to prescribe,
so perhaps the same arguments do not hold. In this article,
we argue that, despite students’ lack of prescribing power,
there are serious ethical issues that should be considered by
medical educators and students when making decisions
about relationships with the pharmaceutical industry.
Potential harms to medical students
Most of the harms we consider here are harms to the social
and moral character of students. Our analysis turns on two
assumptions: first, that the characters of medical students
are shaped in important and long-lasting ways by their
medical education; and second, that some character traits
are ethically more desirable than others. The first assump-
tion is supported by research into the socialisation processes
of medical training, which suggests that students take on
their medical identities in line with prevailing medical
mores.8,9 The second assumption, that some character traits
are more ethically desirable than others, draws upon the
traditions of virtue ethics in medicine. Virtue ethics is
concerned with the kinds of abilities and attitudes that
doctors need to develop and maintain to act morally in their
profession. The list includes virtues such as benevolence,
compassion, integrity and trustworthiness, respectfulness,
honesty and justice.10 In contrast, medical vices have been
described as character traits that accompany the wrong
kinds of ultimate commitments, for example to money, to
power, to science, or to self.11
Implications of pharmaceutical gift giving
What happens when a representative from a pharmaceuti-
cal company gives a gift to a medical student, be it a free
meal, pen, stethoscope, or sponsorship of a conference?
Gift-giving invokes the reciprocity rule, which creates a
feeling of indebtedness in the recipient together with the
desire to repay the favour in some way.4,5 Awareness of this
obligation underlies our reluctance to accept gifts from
those we would prefer not to be indebted to, or when we do
not know what is expected in return. With gift-giving to
medical practitioners, the obligation, although often tacit,
is very real: prescribe this company’s drugs rather than any
other alternatives. Because medical students do not have
the power to prescribe, they may regard themselves as
being free from reciprocal obligations to gift-giving phar-
maceutical companies. This leaves us with two main
possibilities: either the medical students are truly getting
something for nothing, or they are becoming indebted to
the pharmaceutical industry, knowingly or unknowingly. In
the next section we explore the moral implications of each
of these possibilities.
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Something for nothing
Some students will receive material advantage and experi-
ence pleasure when they receive gifts from pharmaceutical
companies, even if small gifts such as pens and free meals
are unlikely to have a significant effect on students’ quality
of life. Larger gifts, such as bursaries and sponsorship of
meetings, may have a more significant effect.
Medical students will rarely, if ever, be able to gain these
benefits for nothing, because drug companies are sophisti-
cated. However, the moral harms that could arise if students
successfully exploited drug companies, or believed that they
did, deserve consideration. Exploiting any person or organi-
sation is unethical and incompatible with the moral charac-
ter development required for optimal patient care. To accept
gifts without accepting reciprocal obligations is to operate
outside of conventional moral expectations — in other
words, to be a free rider. Is this exception to social norms
about gifts similar to other exceptions that medical students
are expected to make during their training, such as asking
probing questions and performing intimate examinations?
During their training, doctors come to take for granted
many of the privileges necessary for patient care. There is a
danger that accepting free gifts might be seen as just another
medical privilege, inducing an unwarranted sense of entitle-
ment among future doctors.12
Normalising something-for-nothing relationships risks a
decreased sensitivity to the moral implications of unequal
relationships. Medical educators must ask themselves if
feelings of entitlement and a readiness to feel wronged in the
absence of gifts are the kinds of character traits that they
would like to encourage in students.
Something for something: hidden strings 
and reciprocal obligations
What harms occur if students, more or less knowingly, take
on reciprocal obligations to the pharmaceutical industry
when they accept gifts? The implications vary with the
degree of awareness. If students are fully aware that pharma-
ceutical companies’ gifts to doctors lead to inappropriate
prescribing, and students accept that they are similarly likely
to be influenced, then gift-taking involves a decision know-
ingly to compromise the interests of patients. Students may
justify this behaviour by appeals to what is “normal”,
because they see their teachers and other doctors accepting
industry gifts. Students may feel that it would be unfair for
them to miss out on benefits that others are receiving.
Psychological research indicates that humans have a “self-
serving bias” that skews judgements about what is fair in
their own favour.4 This bias can be both unintentional and
unconscious, so that students may be unaware that behav-
iour that they feel is justified may be judged otherwise by
people not sharing the benefits. Interestingly, students from
healthcare disciplines who are not offered gifts from the
pharmaceutical industry perceive accepting gifts to be
wrong.13 These factors may help to explain why medical
students often express anger or resentment if they are
challenged to refuse gifts.
It is more likely that students act with less than perfect
knowledge. At some level they may realise that there is no
such thing as a free lunch, but for various reasons may prefer
not to think about and accept the implications. It is common
for humans to understand that others are vulnerable to
being misled by marketing techniques without accepting
that they personally are also vulnerable.14 This illusion of
unique invulnerability leads many doctors to believe that
promotions may influence the prescribing of other doctors,
but do not influence their own prescribing.4 Demonstrating
vulnerability to industry techniques may be a powerful way
of changing students’ attitudes, but, to date, the only
published example involves covert methods, which raise
their own ethical issues.15
A further significant harm is that accepting gifts poten-
tially silences medical students as critics of industry–profes-
sion relationships. This means that society loses the
important contribution to reform provided by young people
who have not yet accepted “normal” professional behav-
iours.17 Given that any “freebies” for students are in fact
paid for by patients and healthcare services, whose pharma-
ceutical costs necessarily include the cost of marketing, this
loss of integrity is acute. The cost of drug promotion in
Australia was around $1–$1.5 billion in 2003.18
Evidence of harm to students
As well as the justifications outlined above, students may
appeal to the lack of empirical evidence that students’
accepting gifts leads to future inappropriate prescribing.
There is no published research comparing the attitudes and
prescribing habits of students exposed to pharmaceutical
representatives during medical school with those protected
from such influences. However, there is evidence that
limiting pharmaceutical industry contacts during postgrad-
uate training produces specialists who perceive drug com-
pany information as less useful, and who see industry
representatives less frequently than specialists who were
exposed during training.18,19 This finding is important,
because perceived usefulness of drug company information
and increased frequency of seeing company representatives
are both risk factors for less appropriate prescribing.6,7
Consequently, the onus of proof is on those who would
claim that medical students are different from postgraduate
trainees.
A study looking at students’ recall of pharmaceutical
companies responsible for giving students textbooks found
that less than a quarter of students could recall the company
involved.20 A similar lack of recall of sponsors’ identities has
been found among doctors, but, despite this, sponsorship
has been demonstrated to be effective in increasing inappro-
priate prescribing of the relevant drugs.21 The implication is
that the gifts of books to students by pharmaceutical
companies can be harmful and effective without students
being aware of it.
The fact that drug companies give gifts to medical
students suggests the companies have evidence that gifts to
students provide a return on investment.
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Even if there is no direct effect on the future prescribing of
specific products, the goodwill engendered by receiving gifts
may be invaluable to the industry in terms of paving the way
for future access and influence once students are qualified
and able to prescribe.20 Pharmaceutical representatives put
a lot of time and effort into personal relationships with
“their” doctors, indicating the importance of relationships
within their overall strategies. Because students may be
flattered by the attention, as well as pleased by gifts from
representatives, a strategy of no contact may be the best way
to avoid establishing relationships of this type.
Duty of care to students
If industry contact with students leads to suboptimal patient
care through inappropriate prescribing, medical educators
have a duty of care both to protect their students from these
influences and to protect their students’ future patients from
the harms of inappropriate prescribing. Would this entail the
prohibition of all industry presence in medical schools and
training hospitals and general practices where students are
placed?
This is the view taken by Kassirer, who has published
extensively on conflict of interest in medicine. He argues
that medical schools should “teach that there is no free
lunch. No free dinner. Or textbooks. Or even a ballpoint
pen”.22 His view is shared by the American Medical Student
Association, which has a PharmFree policy (Box 1) and
pledge for medical students (Box 2). Developing a policy on
relationships with drug companies during 2004 was a major
agenda item at the Australian Medical Students Association
National Council meeting on 12–15 February 2004 (Mr
Matthew Hutchinson, National President, Australian Medi-
cal Students Association, personal communication). As part
of their process, the AMSA National President invited Peter
Mansfield to contribute to the discussions. Policies of
prohibition run the risk of making the prohibited activities
seem all the more desirable. Medical schools and students’
societies instituting such policies should put considerable
time and effort into both explaining the reasoning behind
their policy, and ensuring that all staff comply with it in their
own practices.
One alternative approach would be to ensure that students
give their informed consent before being exposed to indus-
try influences. Discussion of how this might occur is beyond
the scope of this article, but it would need to include
demonstration of the power of marketing techniques, skills
in appraisals of evidence about efficacy of drugs, and
information about the scale and costs of the harms that
occur to patients through inappropriate prescribing.
Conclusion
Both the ethical arguments and the limited available empiri-
cal evidence lead to the conclusion that the best policy is for
medical students to have no contact with drug companies.
The onus is on advocates of any other policy to show that
they can achieve better outcomes.
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TO QUOTE FROM Roger’s article in this issue of the Journal,
“There is growing debate about the ethics of relationships
between the pharmaceutical industry and the medical profes-
sion”.1 Nothing could be more true. However, if this debate is
raging for doctors, then it is sizzling for medical students.
While doctors might not have the time or the inclination to
voice their opinions on the pharmaceutical industry publicly,
Australian medical students seem to have both. The relation-
ship between medical students and the pharmaceutical indus-
try has been hotly debated by the National Council of the
Australian Medical Students’ Association (AMSA) for years.
Yet tangible outcomes and policy have been less palpable,
evidence of just how complex this issue is.
Medicines Australia has imposed self-regulation upon
the industry through its own code of conduct
(www.medicinesaustralia.com.au). This is an important
document in various ways, but, most importantly, it sets
practical boundaries within which the industry can ethically
operate.
So why should medical students bother tackling this issue?
We don’t have script pads or the status to influence prescrib-
ing habits of those who do. Furthermore, with so many
codes of conduct floating around, surely we fall under these
somewhere? Surprisingly not.
Medical students appear to occupy a loophole in an
otherwise highly regulated environment. Codes commonly
use the terms “medical professional” (health professionals
who are unable to prescribe [eg, nurses]) and “non-pre-
scriber” (people without degrees in health fields and who
are unable to prescribe), but do not mention medical
students. As students, and thus non-prescribers, we sit
outside these codes, yet we will prescribe in years to come.
For this reason, AMSA is taking proactive steps to
formulate policy and produce its own code of conduct for
medical students. At the recent meeting (Adelaide, 12–15
March 2004) of the AMSA National Council (which com-
prises one elected representative from each of the 12
medical schools in Australia), various speakers were invited
to give the full spectrum of opinions on the topic. These
guest speakers included a physician and a professor of
clinical pharmacology, along with representatives from
Medicines Australia, a pharmaceutical company and
Healthy Skepticism. After several very informative presenta-
tions, the AMSA Council met in private to discuss the best
way forward.
Feedback from the Council varied greatly, but it was
decided that AMSA’s main responsibility at this stage is to
educate medical students about the differing opinions on
this controversial issue. Following this education campaign,
a nationwide survey will be conducted to gauge medical
students’ opinions at the grass roots. Data from this survey
will then be used, with assistance from the AMSA Council,
to formulate policy and a code of conduct. Although not
binding, this code of conduct will act as a practical guide for
medical students and their societies.
AMSA feels very strongly that, while individual opinions
on this issue may vary greatly, our responsibility is, at the
very least, to educate medical students about the pros and
cons. In this way, medical students can make better-
informed decisions about how far they take their relation-
ships with the pharmaceutical industry.
Matthew Hutchinson
AMSA President
on behalf of the Australian Medical Students’ Association, Adelaide, SA
president@amsa.org.au
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